



Published on *Drug Pipeline* (<https://www.drugpipeline.net>)

Home > Becker Muscular Dystrophy - Pipeline Review, H1 2019

---

# Becker Muscular Dystrophy - Pipeline Review, H1 2019

**Publication ID:**

GMD0319068

**Publication Date:**

March 29, 2019

**Pages:**

61

**Publisher:**

Global Markets Direct

**Region:**

Global [1]

**\$2,000.00**

Publication License Type \*

Single User License (PDF), \$2,000.00

Site License (PDF), \$4,000.00

Global License (PDF), \$6,000.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart



## **Description:**

Becker Muscular Dystrophy - Pipeline Review, H1 2019

### Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Becker Muscular Dystrophy - Pipeline Review, H1 2019, provides an overview of the Becker Muscular Dystrophy (Genetic Disorders) pipeline landscape.

Becker muscular dystrophy (BMD) is one of type of muscular dystrophy, a group of genetic, degenerative diseases primarily affecting voluntary muscles. Symptoms include pain and sensation, difficulty with running, hopping, and jumping, toe walking, breathing problems, cognitive problems and frequent falls.

Becker Muscular Dystrophy - Therapeutics Development Pipeline Overview Number of Products under Development for Becker Muscular Dystrophy, H1 2019

### Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Becker Muscular Dystrophy - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Becker Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Becker Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Becker Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 2 and 1 respectively.

Becker Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

### Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Becker Muscular Dystrophy (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Becker Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Becker Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Becker Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Becker Muscular Dystrophy (Genetic Disorders)

#### Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Becker Muscular Dystrophy (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Becker Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

#### **Table Of Contents:**

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Becker Muscular Dystrophy - Overview

Becker Muscular Dystrophy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Becker Muscular Dystrophy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Becker Muscular Dystrophy - Companies Involved in Therapeutics Development

Catabasis Pharmaceuticals Inc

Italfarmaco SpA

Milo Biotechnology LLC

PTC Therapeutics Inc

ReveraGen BioPharma Inc

Becker Muscular Dystrophy - Drug Profiles

AAV1-Follistatin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARM-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ataluren - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

edasalonexent - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epicatechin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

givinostat - Drug Profile

[Product Description](#)

[Mechanism Of Action](#)

[R&D Progress](#)

[vamorolone - Drug Profile](#)

[Product Description](#)

[Mechanism Of Action](#)

[R&D Progress](#)

[Becker Muscular Dystrophy - Dormant Projects](#)

[Becker Muscular Dystrophy - Discontinued Products](#)

[Becker Muscular Dystrophy - Product Development Milestones](#)

[Featured News & Press Releases](#)

Feb 10, 2016: Catabasis Pharmaceuticals Will Present CAT-1004, a Potential Disease-Modifying Agent in Development for the Treatment of Duchenne Muscular Dystrophy, at the XIV International Conference on Duchenne and Becker Muscular Dystrophy

Jun 30, 2015: Cardero Therapeutics Presents at 2015 Parent Project Muscular Dystrophy Connect Conference

Mar 31, 2015: Cardero Therapeutics Presents at 2015 Muscular Dystrophy Association Scientific Conference

Sep 30, 2014: Becker Trial completed at UC-Davis on the Cardero Therapeutics lead compound

May 31, 2013: Becker Trial initiated at UC-Davis on the Cardero Therapeutics lead compound

Mar 31, 2013: Completed triglyceride trial with Cardero Therapeutics lead compound

[Appendix](#)

[Methodology](#)

[Coverage](#)

[Secondary Research](#)

[Primary Research](#)

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

[List of Tables](#)

[List of Tables](#)

[Number of Products under Development for Becker Muscular Dystrophy, H1 2019](#)

[Number of Products under Development by Companies, H1 2019](#)

[Products under Development by Companies, H1 2019](#)

[Number of Products by Stage and Target, H1 2019](#)

[Number of Products by Stage and Mechanism of Action, H1 2019](#)

[Number of Products by Stage and Route of Administration, H1 2019](#)

[Number of Products by Stage and Molecule Type, H1 2019](#)

[Becker Muscular Dystrophy - Pipeline by Catabasis Pharmaceuticals Inc, H1 2019](#)

Becker Muscular Dystrophy - Pipeline by Italfarmaco SpA, H1 2019  
Becker Muscular Dystrophy - Pipeline by Milo Biotechnology LLC, H1 2019  
Becker Muscular Dystrophy - Pipeline by PTC Therapeutics Inc, H1 2019  
Becker Muscular Dystrophy - Pipeline by ReveraGen BioPharma Inc, H1 2019  
Becker Muscular Dystrophy - Dormant Projects, H1 2019  
Becker Muscular Dystrophy - Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Becker Muscular Dystrophy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

#### **Companies Mentioned:**

Catabasis Pharmaceuticals Inc

Italfarmaco SpA

Milo Biotechnology LLC

PTC Therapeutics Inc

ReveraGen BioPharma Inc

#### **License Types:**

### Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

## Site License (PDF)\*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

## Global License (PDF)\*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

\*If Applicable.



No. 1101, Golden Square, 3rd Floor,  
24th Main, J P Nagar, 1st Phase,  
Bangalore, Karnataka, India- 560078

India: +91-8762746600

info@domain.com

-->

## NAVIGATE

[About Us](#)

[Reports by Region](#)

[FAQ](#)

[Privacy Policy](#)

[TERMS & CONDITIONS](#)

[CONTACT](#)

## RECENT POSTS

[What is drug pipeline research?](#)

March 20

[How to use market research to bring your idea to life?](#)

March 11

[How to gain business insights using syndicated market research?](#)

March 10

---

Source URL: <https://www.drugpipeline.net/global-markets-direct/becker-muscular-dystrophy-pipeline-review-h1-2019>

Links

[1] <https://www.drugpipeline.net/region/global>